Asimov

Despite the many recent breakthroughs in medicine, drug manufacturing remains a lengthy and costly process that is difficult to scale. Asimov seeks to combat this with its intelligent design suite for synthetic biologists, that leverages computer-aided design to help design, simulate, and optimise genetic systems more reliably.

• Recombination - Genetic engineering recombines genes from different species into new systems. At Asimov, we're working toward an ambitious mission that will only be possible by recombining disciplines, backgrounds, and perspectives
• Mission first - Our prime directive is to radically advance humanity’s ability to design living systems, enabling biological technologies with outsized societal benefit. Every decision flows from this mission
• Continuous learning - Biotech is advancing rapidly – we’re surfing that wave and also helping drive it forward. A curiosity to learn new things and an ability to teach other team members is critical to living at the cutting edge
• Thoughtful communication - Our team comes from varied technical domains; we constantly strive to consider people's backgrounds, tailoring our communication to maximize understanding and alignment
• Evolution - As we grow, we’re unafraid to evolve, adapt, and improve all aspects of our company's technology, products, and operations. We must avoid getting trapped in a local optimum

Total funding: $204.7m